ReviewDiabetology & metabolic syndrome2026
Research progress on the molecular mechanism and clinical evidence of glucagon-like peptide-1 receptor agonists in improving sarcopenia.
Review in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patient-Level Multidimensional Response Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is an age-related syndrome characterized by a progressive and extensive decline in skeletal muscle mass and function, leading to serious impairment of the quality of life and poor health prognosis in older adults. As the global population ages, sarcopenia has become a serious public health challenge. Currently, effective treatments for sarcopenia are still very limited. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are gaining increasing attention as first-line agents for the treatment of diabetes and obesity, and with their potential to improve the muscle mass and function, they provide new ideas for the treatment of sarcopenia. This study aims to review the latest research progress in the application of GLP-1RAs in the management of sarcopenia, analyze its key molecular pathways, and explore its role in insulin resistance, mitochondrial function, inflammation, protein metabolism balance, autophagy, and the activation of related signaling pathways. Meanwhile, this article focuses on evaluating the evidence of the current effects of GLP-1RAs on patients’ body composition, muscle mass and function in clinical trials, deeply explores the “dual effects” and heterogeneity of its efficacy, and analyzes the translational dilemma existing between preclinical positive discoveries and clinical outcomes.Furthermore, for the elderly population, this article further discusses the tolerance and nutritional risks faced during the treatment of GLP-1RAs. Further combining nutrition and exercise intervention, the strategies of GLP-1RAs in the comprehensive management of sarcopenia were explored.Finally, this paper points out the future research directions in this field, emphasizing the need for more well-designed and high-quality clinical studies to clarify the exact role, suitable population and long-term safety of GLP-1RAs in the prevention and treatment of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.